AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $134 | -12.4% | 5,395 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $153 | +15.0% | 5,395 | -6.5% | 0.00% | 0.0% |
| Q1 2023 | $133 | -32.8% | 5,769 | -18.3% | 0.00% | -50.0% |
| Q4 2022 | $198 | -99.9% | 7,060 | +1.4% | 0.00% | 0.0% |
| Q3 2022 | $197,000 | +28.8% | 6,963 | +1.0% | 0.00% | +100.0% |
| Q2 2022 | $153,000 | -19.9% | 6,895 | +5.2% | 0.00% | 0.0% |
| Q1 2022 | $191,000 | -60.2% | 6,556 | -55.1% | 0.00% | -50.0% |
| Q4 2021 | $480,000 | +34.8% | 14,588 | +89.0% | 0.00% | -33.3% |
| Q3 2021 | $356,000 | -25.4% | 7,718 | -10.8% | 0.00% | -25.0% |
| Q2 2021 | $477,000 | +22.3% | 8,652 | +14.7% | 0.00% | -73.3% |
| Q1 2021 | $390,000 | +11.1% | 7,545 | -6.9% | 0.02% | +15.4% |
| Q4 2020 | $351,000 | +23.6% | 8,103 | -0.0% | 0.01% | +8.3% |
| Q3 2020 | $284,000 | -34.6% | 8,107 | -0.2% | 0.01% | -40.0% |
| Q2 2020 | $434,000 | -7.9% | 8,120 | -38.8% | 0.02% | +66.7% |
| Q1 2020 | $471,000 | -26.6% | 13,267 | -1.3% | 0.01% | 0.0% |
| Q4 2019 | $642,000 | +87.2% | 13,446 | +27.0% | 0.01% | +71.4% |
| Q3 2019 | $343,000 | -34.3% | 10,585 | +1.1% | 0.01% | -41.7% |
| Q2 2019 | $522,000 | -32.2% | 10,472 | -8.3% | 0.01% | -36.8% |
| Q1 2019 | $770,000 | +48.6% | 11,414 | +1.6% | 0.02% | +26.7% |
| Q4 2018 | $518,000 | -5.6% | 11,229 | +57.8% | 0.02% | +7.1% |
| Q3 2018 | $549,000 | -44.2% | 7,117 | -39.0% | 0.01% | -41.7% |
| Q2 2018 | $983,000 | +14.8% | 11,667 | +11.4% | 0.02% | +4.3% |
| Q1 2018 | $856,000 | +80.6% | 10,473 | +26.4% | 0.02% | +76.9% |
| Q4 2017 | $474,000 | -9.2% | 8,287 | +5.9% | 0.01% | -18.8% |
| Q3 2017 | $522,000 | +46.2% | 7,827 | +12.9% | 0.02% | +33.3% |
| Q2 2017 | $357,000 | +35.2% | 6,930 | +53.2% | 0.01% | -7.7% |
| Q1 2017 | $264,000 | +14.3% | 4,523 | -18.1% | 0.01% | +30.0% |
| Q4 2016 | $231,000 | -8.0% | 5,525 | +16.2% | 0.01% | -33.3% |
| Q3 2016 | $251,000 | +17.8% | 4,753 | +57.3% | 0.02% | -31.8% |
| Q3 2015 | $213,000 | -35.6% | 3,021 | +1.5% | 0.02% | -33.3% |
| Q2 2015 | $331,000 | – | 2,977 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |